Y-mAbs Therapeutics's 15min chart triggers Bollinger Bands Expanding Upward, Bullish Marubozu.

The 15-minute chart for Y-mAbs Therapeutics has recently triggered Bollinger Bands Expanding Upward and Bullish Marubozu at 08/12/2025 09:45, indicating that the market trend is being driven by strong buying activity. As buyers continue to exert control over the market, it is likely that the bullish momentum will persist.

Y-mAbs Therapeutics, Inc. (YMAB) shares surged by 103.3% on August 12, 2025, closing at $8.52. The significant price increase came on high trading volume, with a higher-than-average number of shares changing hands. This substantial movement was triggered by a notable technical indicator: Bollinger Bands Expanding Upward and a Bullish Marubozu signal at 09:45 on August 12, 2025 [1].

The Bollinger Bands Expanding Upward indicates a period of strong buying activity, suggesting that the market trend is being driven by robust demand. The Bullish Marubozu signal, which occurred at the same time, further reinforces this bullish momentum. These signals suggest that buyers are exerting control over the market, and the positive trend is likely to continue [2].

The stock's performance also reflects the company's recent acquisition announcement by SERB Pharmaceuticals. The acquisition, valued at approximately $412 million, is expected to close by the fourth quarter of 2025. Despite the expected quarterly loss of $0.27 per share and a decrease in revenues to $18.43 million, the acquisition has driven investor confidence and contributed to the stock's significant price increase [3].

Y-mAbs Therapeutics has consistently exceeded consensus revenue estimates over the last four quarters, with two instances of surpassing consensus EPS estimates in the past year. The company's earnings report for the second quarter of 2025, which showed a quarterly loss of $0.07 per share and revenues of $19.53 million, further demonstrates its ability to beat expectations [4].

Investors are closely monitoring the company's earnings outlook and estimate revisions, with the current consensus EPS estimate for the coming quarter at -$0.28 and revenues expected to be $20.56 million. The industry's outlook also plays a role in the stock's performance, with the Medical - Biomedical and Genetics industry currently ranked in the bottom 43% of Zacks industries [4].

Despite the industry's challenges, Y-mAbs Therapeutics' track record of outperforming peers suggests potential resilience. The company faces competition from other industry players like Cue Biopharma, Inc. (CUE), which is expected to post a quarterly loss of $0.13 per share for the quarter ended June 2025 [4].

In conclusion, Y-mAbs Therapeutics' recent stock surge can be attributed to the Bollinger Bands Expanding Upward and Bullish Marubozu signals, as well as the acquisition announcement by SERB Pharmaceuticals. Investors should closely monitor the company's future earnings and strategic developments for further insights into its potential growth.

References:
[1] https://www.ainvest.com/news/mabs-therapeutics-q2-earnings-revenue-meets-expectations-eps-consensus-2508/
[2] https://www.nasdaq.com/articles/ymabs-therapeutics-ymab-surges-1033-indication-further-gains
[3] https://finance.yahoo.com/news/ymabs-therapeutics-ymab-surges-103-135000761.html
[4] https://www.nasdaq.com/articles/y-mabs-therapeutics-inc-ymab-reports-q2-loss-tops-revenue-estimates